MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
Eligible age
18+ yrs
Accepts
All genders
Locations
29 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The FLEX Registry will be implemented to operate as a large-scale, population based, prospective registry. All patients with stage I to III breast cancer who receive MammaPrint® and BluePrint testing on a primary breast tumor are eligible for entry into the FLEX Registry, which is intended to enable additional study arms at low incremental effort and cost. FLEX Registry will utilize an adaptive design, where additional targeted substudies and arms can be added after the initial study is opened.
Sponsor: Agendia
You may qualify if…
- ✓ Stage I, II, or III patients who receive MammaPrint, with or without BluePrint testing (male or female)
- ✓ Informed consent form signed on the same day or before enrollment
- ✓ New primary lesion
You may not qualify if…
- ✕ Tumor sample shipped to Agendia with ≤ 30% tumor cells or that fails QA or QC criteria
- ✕ Metastatic disease
- ✕ Recurrent disease
- ✕ Stage 0 disease
Where it's recruiting
Birmingham
Anchorage
Phoenix · Tucson
Bakersfield · Palm Springs · Redding · San Francisco …
Aurora · Denver · Lakewood · Vail
Waterbury
Newark
Atlantis · Boca Raton · Clearwater · Daytona Beach …
Albany · Atlanta · Brunswick · Decatur …
Chicago · Elk Grove Village · Hoffman Estates · Oak Lawn
Fort Wayne
Shreveport
Source: ClinicalTrials.gov · NCT03053193 · last updated 2025-08-20